Taligen Adds Maraganore to Board

4/15/10

Taligen Therapeutics, the Cambridge, MA-based developer of treatments for inflammatory and autoimmune disorders, said today it has added John Maraganore to its board of directors. Maraganore is the CEO of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) a leader in developing RNA interference treatments. Separately, Taligen said it added two members to its management team: Sven Ante (Bill) Lundberg as chief medical officer, and Karen Tubridy as vice president of clinical operations and regulatory affairs.

By posting a comment, you agree to our terms and conditions.